Xiaobin Wu Biography and Net Worth

COO of Beigene

Xiaobin Wu, Ph.D. joined BeiGene in 2018 and currently serves as President, Chief Operating Officer.

Dr. Wu previously was Country Manager of Pfizer China and the Regional President of Pfizer Essential Health for Greater China from 2009 to 2018. Under Dr. Wu’s leadership, Pfizer expanded its portfolio and organization, significantly grew sales, initiated innovative marketing programs, and established its position as a leading multinational pharmaceutical company in China. Prior to Pfizer, Dr. Wu served as President and Managing Director of Wyeth China and Hong Kong (2004-2009). Before joining Wyeth, Dr. Wu was General Manager of Bayer Healthcare in China (2001-2004). He started his career in 1992 in sales and marketing with Bayer in Germany.

Dr. Wu has a Ph.D. in biochemistry and pharmacology and a master’s degree in molecular biology from the University of Konstanz in Germany.

What is Xiaobin Wu's net worth?: The estimated net worth of Xiaobin Wu is at least $1.24 million as of September 17th, 2024. Dr. Wu owns 4,500 shares of Beigene stock worth more than $1,244,385 as of June 13th. This net worth approximation does not reflect any other investments that Dr. Wu may own. Learn More about Xiaobin Wu's net worth.
How do I contact Xiaobin Wu?: The corporate mailing address for Dr. Wu and other Beigene executives is C/O MOURANT GOVERNANCE SERVICES (CAYMAN), 94 SOLARIS AVENUE, CAMANA BAY, GRAND CAYMAN, E9, KY1-1108. Beigene can also be reached via phone at 13459494123 and via email at [email protected]. Learn More on Xiaobin Wu's contact information.
Has Xiaobin Wu been buying or selling shares of Beigene?: In the last ninety days, Xiaobin Wu has sold $15,100,161.50 in Beigene stock. Most recently, Xiaobin Wu sold 1,934 shares of the business's stock in a transaction on Friday, June 6th. The shares were sold at an average price of $253.15, for a transaction totalling $489,592.10. Learn More on Xiaobin Wu's trading history.
Who are Beigene's active insiders?: Beigene's insider roster includes Chan Lee (SVP), John Oyler (CEO), Lai Wang (Global Head of R&D), Lai Wang (Insider), Xiaodong Wang (Insider), and Xiaobin Wu (COO). Learn More on Beigene's active insiders.
Are insiders buying or selling shares of Beigene?: In the last twelve months, insiders at the sold shares 19 times. They sold a total of 1,238,865 shares worth more than $317,860,315.41. The most recent insider tranaction occured on June, 11th when insider Titus B. Ball sold 134 shares worth more than $34,620.24. Insiders at Beigene own 6.6% of the company. Learn More about insider trades at Beigene.
Information on this page was last updated on 6/11/2025.

Xiaobin Wu Insider Trading History at Beigene

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction
6/6/2025	Sell	1,934	$253.15	$489,592.10
4/1/2025	Sell	51,921	$281.40	$14,610,569.40
3/5/2025	Sell	51,921	$261.59	$13,582,014.39
2/20/2025	Sell	21,267	$240.07	$5,105,568.69
2/18/2025	Sell	30,654	$240.74	$7,379,643.96

Xiaobin Wu Buying and Selling Activity at Beigene

Beigene Company Overview

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.

Today's Range

Now: $271.95

$268.69

$272.82

50 Day Range

MA: $240.18

$206.32

$276.53

2 Week Range

Now: $271.95

$141.31

$287.88

Volume

170,927 shs

Average Volume

448,967 shs

Market Capitalization

$32.19 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.3